2. Efficacy and Safety of Edoxaban in Patients With AF and HF

4. HF in ENGAGE AF-TIMI 48 Select Baseline Characteristics

5. Efficacy and Safety Outcomes by HF Class

6. Efficacy and Safety Outcomes by Treatment

7. Conclusions

8. Patients With Prior Cerebrovascular Event

9. ENGAGE AF-TIMI 48 Efficacy and Safety

10. Edoxaban vs VKA in Patients With Previous Cerebrovascular Events

11. Assessing Risk CHA2DS2-VASc

12. Absolute Risk in Patients With Previous Cerebrovascular Events

13. Conclusions

14. Sudden Cardiac Death in AF

16. Causes of Death in ENGAGE AF-TIMI 48

17. Characterization of SCD Events

18. Predictors of SCD in ENGAGE AF

19. Conclusions

20. Impact of Renal Function in ENGAGE AF-TIMI 48

21. Edoxaban Renal Implications in ENGAGE AF-TIMI 48

23. Outcomes in ENGAGE AF-TIMI 48 Based on CrCl

24. Edoxaban Concentrations Based on Renal Clearance

25. Conclusions

26. Impact of NOACs in Treating AF: Insights From ENGAGE AF-TIMI 48

27. Percentage of Strokes Attributable to AF Increases With Age

28. AF and Stroke Summary of Randomized Studies

31. NOAC 4-Trial Meta-Analysis Prespecified Meta-Analysis of All 71,683 Patients

32. Conclusions

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)